title: Photoallergic contact dermatitis from topical diclofenac in Solaraze gel.
abstract: Solaraze gel (Shire Deutschland GmbH & Co. KG, Cologne, Germany) containing 3% diclofenac has been licensed in 2001 as a topical treatment for actinic keratoses. It is commonly used in dermatological practice. Undesirable effects are believed to be rare but include pruritus, paresthesia and application-site reactions (dry skin, rash, erythema, contact dermatitis and vesicobullous eruptions). Recently, a few cases of contact dermatitis due to three different allergens including diclofenac have been reported (1,2).
authors.affiliation: Klinik für Hautkrankheiten und Allergologie, HUMAINE Vogtland-Klinikum Plauen, Plauen, Germany. lutz.kowalzick@web.de
authors.forename: L
authors.initials: L
authors.lastname: Kowalzick
authors.forename: H
authors.initials: H
authors.lastname: Ziegler
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects; D017454:Dermatitis, Photoallergic / Q000175:diagnosis / Q000209:etiology*; D004008:Diclofenac / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005782:Gels; D006801:Humans; D007642:Keratosis / Q000188:drug therapy; D010328:Patch Tests
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005782:Gels; D004008:Diclofenac